As
filed with the Securities and Exchange Commission on December 8, 2023
Registration
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
S-8
REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933
UNICYCIVE
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
81-3638692 |
(State
or other jurisdiction of
incorporation or organization) |
|
(I.R.S.
Employer
Identification No.) |
4300
El Camino Real, Suite 210
Los
Altos, CA 94022
(650)
351-4495
(Address
of principal executive offices) (Zip Code)
Unicycive
Therapeutics, Inc. Amended and Restated Omnibus 2021 Equity Incentive Plan
(Full
title of the plan)
Shalabh
Gupta, M.D.
Chief
Executive Officer
Unicycive
Therapeutics, Inc.
4300
El Camino Real, Suite 210
Los
Altos, CA 94022
(650)
351-4495
(Name
and Address of agent for service)
(650)
351-4495
(Telephone
number, including area code, of agent for service)
With
copies to:
Jeffrey
Fessler
Sheppard,
Mullin, Richter & Hampton LLP
30
Rockefeller Plaza
New
York, NY 10012
Tel:
(212) 653-8700
Fax:
(212) 653-8701
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
Emerging
growth company |
☒ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐
PART
I
INFORMATION
REQUIRED IN THE SECTION 10(a) PROSPECTUS
Item
1. Plan Information.
Unicycive
Therapeutics, Inc. (the “Company”) will provide each recipient (the “Recipients”) of a grant under the Unicycive
Therapeutics, Inc. Amended and Restated Omnibus 2021 Equity Incentive Plan (the “Restated Plan”) with documents that contain
information related to the Restated Plan, and other information including, but not limited to, the disclosure required by Item 1 of Form
S-8, which information is not required to be and is not being filed as a part of this Registration Statement on Form S-8 (the “Registration
Statement”) or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act of 1933, as amended (the
“Securities Act”). The foregoing information and the documents incorporated by reference in response to Item 3 of Part II
of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities
Act. A Section 10(a) prospectus will be given to each Recipient who receives common stock covered by this Registration Statement, in
accordance with Rule 428(b)(1) under the Securities Act.
Item
2. Registrant Information and Employee Plan Annual Information.
We
will provide to each Recipient a written statement advising of the availability of documents incorporated by reference in Item 3 of Part
II of this Registration Statement (which documents are incorporated by reference in this Section 10(a) prospectus) and of documents required
to be delivered pursuant to Rule 428(b) under the Securities Act without charge and upon written or oral request by contacting:
Shalabh
Gupta, M.D.
Chief
Executive Officer
Unicycive
Therapeutics, Inc.
4300
El Camino Real, Suite 210
Los
Altos, CA 94022
PART
II
INFORMATION
NOT REQUIRED IN THE PROSPECTUS
Item 3.
Incorporation of Documents by Reference.
The
following documents filed by the Registrant with the Commission pursuant to the Securities Act of 1933, as amended (the “Securities
Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:
| ● | The
Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022 filed
with the SEC on March 31, 2023; |
| ● | The
Registrant’s Current Reports on Form 8-K filed with the SEC on February 2, 2023; February 7, 2023; March 2, 2023; March 6, 2023; March 30, 2023; March 31, 2023; April 10, 2023; May 16, 2023; May 23, 2023; June 26, 2023; June 30, 2023; July 26, 2023; July 31, 2023; August 15, 2023; August 31, 2023; September 6, 2023; September 25, 2023; October 23, 2023; and November 14, 2023 (except for any portions of such Current Reports on Form 8-K furnished pursuant
to Item 2.02 and/or Item 7.01 thereof and any corresponding exhibits thereto not filed with
the SEC); |
| ● | The
Registrant’s Definitive Proxy Statement on Schedule 14A for the Company’s 2023
annual meeting of stockholders filed with the SEC on April 28, 2023; |
| ● | The
description of the Registrant’s common stock contained in the registration statement
on Form 8-A filed with the SEC on July 6, 2021, including any amendment or report filed for
the purpose of updating that description. |
| ● | All
other reports and documents filed by the Company pursuant to Section 13(a), 13(c), 14 or
15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01
of Form 8-K and exhibits furnished on such form that relate to such items) subsequent to
the date of this Registration Statement and prior to the filing of a post-effective amendment
to this Registration Statement that indicates that all securities offered hereby have been
sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated
by reference into this Registration Statement and to be a part hereof from the date of filing
such reports and documents. Any statement contained in a document incorporated or deemed
to be incorporated by reference herein shall be deemed to be modified or superseded for purposes
of this Registration Statement to the extent that a statement herein or in any subsequently
filed document that also is or is deemed to be incorporated by reference herein modifies
or supersedes such statement. Any such statement so modified or superseded shall not constitute
a part of this Registration Statement, except as so modified or superseded. |
Item
4. Description of Securities.
Not
applicable.
Item 5.
Interests of Named Experts and Counsel.
Not
applicable.
Item 6.
Indemnification of Directors and Officers.
Section
145 of the General Corporation Law of the State of Delaware provides that a corporation may indemnify directors and officers as well
as other employees and individuals against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement
in connection with specified actions, suits and proceedings whether civil, criminal, administrative, or investigative, other than a derivative
action by or in the right of the corporation, if they acted in good faith and in a manner they reasonably believed to be in or not opposed
to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe their
conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification extends only to
expenses, including attorneys’ fees, incurred in connection with the defense or settlement of such action and the statute requires
court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation.
The statute provides that it is not exclusive of other indemnification that may be granted by a corporation’s certificate of incorporation,
bylaws, disinterested director vote, stockholder vote, agreement or otherwise.
Our
Fourth Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws provide for indemnification of directors
and officers to the fullest extent permitted by law, including payment of expenses in advance of resolution of any such matter.
We
have entered into separate indemnification agreements with our directors and officers. Each indemnification agreement provides, among
other things, for indemnification to the fullest extent permitted by law and our certificate of incorporation and bylaws against any
and all expenses, judgments, fines, penalties and amounts paid in settlement of any claim. The indemnification agreements provide for
the advancement or payment of all expenses to the indemnitee and for reimbursement to us if it is found that such indemnitee is not entitled
to such indemnification under applicable law and our certificate of incorporation and bylaws.
We
maintain standard policies of insurance under which coverage is provided (a) to our directors and officers against loss rising from claims
made by reason of breach of duty or other wrongful act, and (b) to us with respect to payments which we may make to such officers and
directors pursuant to the above indemnification provision or otherwise as a matter of law.
Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us
under the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable.
Item
7. Exemption from Registration Claimed.
Not
applicable.
Item
8. Exhibits.
See
the attached Exhibit Index on the page immediately following the signature pages hereto, which is incorporated herein by reference.
Item
9. Undertakings.
A.
The undersigned Registrant hereby undertakes:
1.
To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
(i)
To include any prospectus required by section 10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration
Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration
Fee” table in the effective Registration Statement.
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or
any material change to such information in the Registration Statement;
Provided,
however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section
15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.
2.
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.
3.
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.
B.
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of
the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing
of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in
the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering
of such securities at that time shall be deemed to be the initial bona fide offering thereof.
C.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons
of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.
SIGNATURES
Pursuant
to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that
it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Los Altos, State of California, on the 8th day of December, 2023.
|
UNICYCIVE THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/ Shalabh
Gupta |
|
|
Shalabh Gupta |
|
|
Chief Executive Officer |
POWER
OF ATTORNEY
KNOW
ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Shalabh Gupta, his or her true and
lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him and in his name, place and stead, in any
and all capacities to sign any or all amendments (including, without limitation, post-effective amendments) to this Registration Statement,
any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and any or all pre- or
post-effective amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith,
with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform
each and every act and thing requisite and necessary to be done in and about the premises, as fully for all intents and purposes as he
or she might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or substitutes
for him, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the
capacities and on the dates indicated.
SIGNATURE |
|
TITLE |
|
DATE |
|
|
|
|
|
/s/
Shalabh Gupta |
|
Chief Executive Officer, President
and Chairman |
|
December
8, 2023 |
Shalabh
Gupta |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/
John Townsend |
|
Chief Financial Officer |
|
December
8, 2023 |
John
Townsend |
|
(Principal Financial and Accounting
Officer) |
|
|
|
|
|
|
|
/s/
John Ryan |
|
Director |
|
December
8, 2023 |
John
Ryan, M.D., Ph.D. |
|
|
|
|
|
|
|
|
|
/s/
Sandeep Laumas |
|
Director |
|
December
8, 2023 |
Sandeep
Laumas, M.D. |
|
|
|
|
|
|
|
|
|
/s/
Sara Kenkare-Mitra |
|
Director |
|
December
8, 2023 |
Sara
Kenkare-Mitra |
|
|
|
|
|
|
|
|
|
/s/
Gaurav Aggarwal |
|
Director |
|
December
8, 2023 |
Gaurav
Aggarwal |
|
|
|
|
EXHIBIT
INDEX
Exhibit
Number |
|
Description |
3.1 |
|
Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.4 to Form S-1 filed on May 21, 2021) |
3.2 |
|
Amended and Restated Bylaws (incorporated by reference to Exhibit 3.5 to Form S-1 filed on May 21, 2021) |
4.1 |
|
Specimen stock certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4,1 to Form S-1 filed on May 21, 2021) |
5.1 |
|
Opinion of Sheppard, Mullin, Richter & Hampton LLP |
10.1 |
|
Unicycive Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan (incorporated by reference to Exhibit C to Definitive Proxy Statement filed on April 28, 2023) |
23.1 |
|
Consent of Mayer Hoffman McCann P.C., independent registered public accounting firm |
23.2 |
|
Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 5.1) |
24.1 |
|
Power of Attorney (included on signature page) |
107 |
|
Filing Fee Table |
-6-
Exhibit 5.1
|
Sheppard, Mullin, Richter & Hampton LLP
30 Rockefeller Plaza
New York, New York 10112-0015
212.653.8700 main
212.653.8701 fax
www.sheppardmullin.com |
December 8, 2023
VIA ELECTRONIC MAIL
Unicycive Therapeutics, Inc.
4300 El Camino Real, Suite 210
Los Altos, CA 94022
Re: |
Registration Statement on Form S-8 |
Ladies and Gentlemen:
You have requested our opinion
with respect to certain matters in connection with the filing by Unicycive Therapeutics, Inc., a Delaware corporation (the “Company”),
of a Registration Statement on Form S-8 (the “Registration Statement”) under the Securities Act of 1933, as amended (the
“Securities Act”), with the U.S. Securities and Exchange Commission (the “Commission”), covering up to 11,473,670
shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), which
may be issued pursuant to the Company’s Amended and Restated 2021 Omnibus Equity Incentive Plan (the “Restated Plan”)
and the Company’s 2021 Omnibus Equity Incentive Plan (the “2021 Plan” and together with the Restated Plan, the “Plans”).
This opinion (this “Opinion”)
is being furnished in accordance with the requirements of Item 8 of Form S-8 and Item 601(b)(5)(i) of Regulation S-K.
In connection with this Opinion,
we have reviewed and relied upon the Registration Statement, the Company’s Certificate of Incorporation as in effect on the date
hereof, the Company’s Bylaws, as in effect on the date hereof, the proceedings taken by the Company with respect to the authorization
and adoption of the Plan, resolutions adopted by the board of directors of the Company, and such other documents, records, certificates,
memoranda and other instruments as we deem necessary as a basis for this Opinion.
With respect to the foregoing
documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the
conformity to original of all documents submitted to us as certified or reproduced copies. We have also assumed that the Shares will be
uncertificated in accordance with Section 158 of the Delaware General Corporation Law, and the transfer agent therefor will register
the purchaser thereof as the registered owner of any uncertificated Shares on its stock transfer books and records. We have further assumed
that (a) shares of Common Stock currently reserved for issuance under the Plans will remain available for the issuance of the Shares,
and (b) neither the Company’s charter documents nor any of the proceedings relating to either the Plans or any of the award
agreements relating to the Shares will be rescinded, amended or otherwise modified prior to the issuance of the Shares. We have also obtained
from public officials and officers of the Company certificates or comparable documents as to certain factual matters and, insofar as this
Opinion is based on matters of fact, we have relied on such certificates and comparable documents without independent investigation. We
have made such other investigations as we have deemed relevant and necessary in connection with the opinions hereinafter set forth.
On the basis of the foregoing,
and in reliance thereon, we are of the opinion that the Shares, when issued and sold in the manner referred to in the Plans against proper
payment and consideration thereof and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid,
and nonassessable.
We consent to the filing of
this Opinion as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not thereby admit that we are included in
the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the
Commission promulgated thereunder.
We express no opinion as to
matters governed by any laws other than the Delaware General Corporation Law and reported decisions of the Delaware courts interpreting
such law.
This Opinion is rendered as
of the date first written above, and we disclaim any obligation to advise you of facts, circumstances, events or developments which hereafter
may be brought to our attention and which may alter, affect or modify the opinion expressed herein. Our opinion is expressly limited
to the matters set forth above, and we render no opinion, whether by implication or otherwise, as to any other matters relating to the
Company, the Shares, the Plans, the award agreements related to the Shares, or the Registration Statement.
Respectfully Submitted, |
|
|
|
/s/ Sheppard, Mullin, Richter & Hampton LLP |
|
Sheppard, Mullin, Richter & Hampton LLP |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We consent to the incorporation by reference in this
Registration Statement on Form S-8 and related Prospectus, of our report dated March 30, 2023 with respect to the financial statements
of Unicycive Therapeutics, Inc. (Company) as of December 31, 2022 and 2021 and for each of the two years in the period ended December
31, 2022, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.
/s/ Mayer Hoffman McCann P.C.
San Diego, California
December 8, 2023
Exhibit
107
Calculation
of Filing Fee Tables
FORM
S-8
(Form
Type)
UNICYCIVE
THERAPEUTICS, INC.
(Exact
Name of Registrant as Specified in its Charter)
Table
1: Newly Registered Securities
| |
Security
Type | |
Security
Class
Title | |
Fee
Calculation Rule | |
Amount
Registered (1) |
| |
Proposed
Maximum
Offering
Price Per
Share |
| |
Maximum
Aggregate
Offering
Price | | |
Fee
Rate | | |
Amount
of
Registration
Fee | |
Fees
to Be Paid | |
Equity | |
Common Stock, par value $0.001
per share | |
Other(2) | |
| 11,473,670 |
| |
$ | 0.54 |
(2) | |
$ | 6,195,782 | | |
| 0.00014760 | | |
$ | 915 | |
Fees
Previously Paid | |
| |
| |
| |
| |
| |
| |
| |
| | | |
| | | |
| | |
| |
Total Offering Amounts | |
| |
| |
| |
| |
| | | |
| | | |
$ | 915 | |
| |
Total Fees Previously Paid | |
| |
| |
| |
| |
| | | |
| | | |
| - | |
| |
Total
Fee Offsets | |
| |
| |
| |
| |
| | | |
| | | |
| - | |
| |
Net Fee
Due | |
| |
| |
| |
| |
| | | |
| | | |
$ | 915 | |
| (1) | Pursuant
to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”),
this Registration Statement shall also cover any additional shares of common stock, par value
$0.001 per share (“Common Stock”), of Unicycive Therapeutics, Inc. (the “Registrant”)
that become issuable under the Registrant’s Amended and Restated 2021 Omnibus Equity
Incentive Plan (the “Plan”), by reason of any stock dividend, stock split, recapitalization
or other similar transaction that increases the number of the outstanding shares of the Registrant’s
common stock. In addition, pursuant to Rule 416(c) under the Securities Act, this Registration
Statement shall also cover an indeterminate amount of interests to be offered or sold pursuant
to the employee benefit plan described herein. |
| (2) | Estimated
solely for purposes of calculating the registration fee pursuant to Rules 457(c) and 457(h)
of the Securities Act by averaging the high and low sales prices of the Registrant’s
Common Stock reported on The Nasdaq Capital Market on December 6, 2023, which date is within
five business days prior to the filing of this Registration Statement. |
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Unicycive Therapeutics (NASDAQ:UNCY)
Historical Stock Chart
From Oct 2023 to Oct 2024